Pharmacodynamic evaluation of oral estradiol nanoparticles in estrogen deficient (ovariectomized) high-fat diet induced hyperlipidemic rat model.
作者信息
Mittal G, Chandraiah G, Ramarao P, Ravi Kumar M N V
机构信息
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
出版信息
Pharm Res. 2009 Jan;26(1):218-23. doi: 10.1007/s11095-008-9725-x. Epub 2008 Sep 12.
PURPOSE
It is believed that estrogen deficiency contributes importantly to the pathogenesis of menopausal metabolic syndrome and symptoms can be ameliorated with estradiol therapy. The present study reports efficacy of 17-beta estradiol encapsulated nanoparticles in treating the postmenopausal dyslipidemic condition.
MATERIALS AND METHODS
Estradiol encapsulated poly(lactide-co-glycolide) (PLGA) nanoparticles were prepared by emulsion-diffusion-evaporation method and evaluated in estrogen deficient (ovariectomized) high fat diet induced hyperlipidemic rat model.
RESULTS
The results obtained showed that estradiol nanoparticles were equally/more effective in treatment of estrogen deficient hyperlipidemic conditions at three times reduced dose and frequency in comparison to that of drug suspension administered orally.
CONCLUSION
Together, these results demonstrate the ability of nanoparticles in improving oral bioavailability/efficacy of estradiol.
Zotero 插件